HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Molecular Targeted Therapy

Subscribe to New Research on Molecular Targeted Therapy

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Also Known As:

Targeted Molecular Therapy; Molecular Targeted Therapies; Molecular Therapies, Targeted; Molecular Therapy, Targeted; Targeted Molecular Therapies; Targeted Therapies, Molecular; Targeted Therapy, Molecular; Therapies, Molecular Targeted; Therapies, Targeted Molecular; Therapy, Molecular Targeted; Therapy, Targeted Molecular

Networked: 958 relevant articles (75 outcomes, 83 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 15318
- Drug Therapy: 178671
  - Molecular Targeted Therapy: 958

Experts

1.	Jagannathan, Jyothi P: 13 articles (10/2015 - 04/2012)
2.	Ramaiya, Nikhil H: 12 articles (10/2015 - 04/2012)
3.	Krajewski, Katherine M: 11 articles (10/2015 - 04/2012)
4.	Wen, Patrick Y: 11 articles (02/2015 - 02/2003)
5.	Shinagare, Atul B: 9 articles (10/2015 - 11/2012)
6.	Kudo, Masatoshi: 9 articles (09/2012 - 01/2008)
7.	Sobue, Gen: 8 articles (07/2012 - 08/2006)
8.	Awada, Ahmad: 8 articles (08/2010 - 01/2002)
9.	Tirumani, Sree Harsha: 6 articles (10/2015 - 01/2013)
10.	Katsuno, Masahisa: 6 articles (07/2012 - 08/2006)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2014 - "Although surgical treatment may be beneficial for tumors without systemic involvement, new chemotherapeutic agents and molecular targeted therapy should be implemented to improve the oncologic outcome in both early and late stage disease." 01/01/2013 - "Efficacy of molecular targeted therapies has been better in cancer patients with high expression of actionable molecules defined as cognate target molecules. " 10/01/2008 - "A better understanding of the biology of the tumor led to the discovery of molecular targeted therapies resulting in significant improvement in outcome for this common malignancy. " 08/01/2005 - "Testing whether molecular targeted therapies of adult cancers are also effective against childhood cancers might allow the rapid introduction of these exciting new agents into the pediatric clinic. " 02/01/2014 - "The use of molecular targeted therapies has improved median overall survival (OS) in a limited group of NSCLC patients whose tumors harbor specific genetic alterations. "
2.	Neoplasm Metastasis (Metastasis) 01/01/2012 - "In recent years, considerable attention has been paid to molecular targeted therapies to improve the efficacy of the available chemotherapeutic regimens in order to increase the downsizing rate of liver metastases and increase resectability. " 01/01/2011 - "Molecular targeted therapy may be an effective treatment for breast metastasis." 10/01/2013 - "Many clinical studies have reported the effectiveness of molecular targeted therapies for brain metastases. " 07/01/2013 - "In the era of molecular targeted therapy, every radiologist who interprets oncologic studies needs to be aware of the unusual patterns of treatment response and should be able to differentiate pseudoprogression of liver metastases from true progression because this distinction has an important impact on clinical management." 01/01/2015 - "We believe that advances in the understanding of breast to brain metastasis pathogenesis will lead to targeted molecular therapies and to improvements in the ability to prospectively identify patients at increased risk for developing intracranial disease. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 06/01/2012 - "Although molecular targeted therapy has improved the clinical outcome of metastatic renal cell carcinoma, a complete response is rare and there are various side effects. " 06/01/2015 - "Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma." 04/01/2015 - "[Prognostic factors and efficacy of molecular targeted therapy for metastatic clear cell renal cell carcinoma]." 05/01/2015 - "The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. " 10/01/2015 - "The present review considers ongoing translational research efforts on clinicopathological, molecular biological, and genetic prognostic and/or predictive factors for metastatic renal cell carcinoma patients in the era of molecular-targeted therapy, and discusses the clinical implications of these findings. "
4.	Hepatocellular Carcinoma (Hepatoma) 01/01/2013 - "Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma (HCC). " 01/01/2009 - "The positive result of these two trials are the proof of the efficacy of molecular targeted therapies in hepatocellular carcinoma and opens the door to multipathway blockade and the use of these targeted therapies in the adjuvant setting. " 03/01/2014 - "Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future." 07/01/2011 - "Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies." 01/01/2010 - "Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma."
5.	Melanoma (Melanoma, Malignant) 01/01/2013 - "Molecular targeted therapies have shown promise in the management of various malignancies, including melanoma, with lower toxicity profiles and better overall survival as compared with conventional therapy. " 01/01/2015 - "Recent studies have shown that immunotherapies and molecular targeted therapies are effective for advanced melanoma. " 08/01/2015 - "Thanks to modern techniques, molecular signatures for melanoma are now identifiable and have opened new horizons in the treatment of metastatic disease with molecular-targeted therapies. " 05/20/2015 - "Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy." 04/01/2015 - "Systemic targeted molecular therapy, in the form of a selective BRAF inhibitor with or without a MEK inhibitor, is a standard treatment for patients with BRAF V600 mutation-positive melanoma with unresectable stage III and IV disease. "

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	Monoclonal Antibodies
3.	Epidermal Growth Factor Receptor (EGF Receptor)
4.	cetuximab (Erbitux)
5.	Proteasome Endopeptidase Complex (Proteasome)
6.	Histone Deacetylase Inhibitors
7.	Phosphotransferases (Kinase)
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	Biological Markers (Surrogate Marker)
10.	sorafenib (BAY 43-9006)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Radiotherapy
4.	Therapeutics
5.	Nephrectomy